Cleveland BioLabs (CBLI) Falls On Good News
August 17, 2009 · Filed Under R&D
Cleveland BioLabs, Inc. (NASDAQ: CBLI) has moved on news that it received a patent allowance from USPTO to cover the method of protecting a mammal from radiation using flagellin or its derivatives. This patent was already granted by the nine member countries of the Eurasian Patent Organization (EAPO) and two additional countries.
Oddly enough, the stock is down 5% to $4,20. Investors may feel that most of the news was already in the market.
The company recently hit a 52-week high after releasing strong earnings
Douglas A. McIntyre
